Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Drop in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 257,100 shares, a decrease of 13.4% from the August 31st total of 296,800 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average trading volume of 82,900 shares, the short-interest ratio is presently 3.1 days.

Aileron Therapeutics Stock Up 1.7 %

ALRN opened at $3.65 on Friday. The stock has a market cap of $78.89 million, a PE ratio of -1.14 and a beta of 2.33. The business has a 50 day moving average of $2.57 and a 200-day moving average of $3.60. Aileron Therapeutics has a 52 week low of $1.01 and a 52 week high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20). Equities analysts anticipate that Aileron Therapeutics will post -1.41 EPS for the current year.

Hedge Funds Weigh In On Aileron Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. University of Texas Texas AM Investment Management Co. bought a new position in shares of Aileron Therapeutics during the second quarter valued at $4,925,000. Warberg Asset Management LLC purchased a new position in Aileron Therapeutics in the second quarter worth about $86,000. Texas Capital Bank Wealth Management Services Inc raised its holdings in Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after buying an additional 10,398 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in shares of Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after buying an additional 209,367 shares in the last quarter. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).